MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Caryn Mickelson, PharmD; Robin Moody, MPH; Russ Huffman, PMHNP; Mark Helm, MD; Cat Livingston, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Sara Fletcher, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Megan Herink, PharmD; Gary Karagodsky, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH

Audience: Amy Breen, Teva; Amy Burns, AllCare CCO; Heidi Behm, OHA Public Health TB Program; Brandie Feger, Advanced Health; Charlie Lovan, AbbVie; Chris Tanaka, ViiV HealthCare; Danielle Addis, AGIOS; Gloria Zepeda, P4 Pharmacy Student; Jason Kniffin; John Stancil, Artia Solutions; Jonathan Frochtzwaig, CAP; Josh Whittington, BMS; Kaitlyn Molina, Samaritan Health Plan; Kevin Hintzorne, LEO Pharma; Kristen Tjaden; Liz Breitenstein, OHA; Lori Howarth, Bayer; Mark Germann, LEO Pharma; Mark Kantor, AllCare Health; Matt Worthy, OHSU; Melissa Snider, Gilead Sciences; Michael Foster, BMS; Mike Donabedian, Sarepta Therapeutics; Olaf Reinwald, Global Blood Therapeutics; Patrick Harvey, MSL Supernus Pharmaceuticals; Rick Frees, Vertex; Rochelle Yang, Teva; Saghi Maleki, Takeda Pharmaceuticals; Tiffany Jones, PacificSource; Tiina Andrews, Umpqua Health Alliance; Trish Olson, SK Life Science; Uche Mordi, BMS; Valerie Ng, LEO Pharma; Victoria Romo-LeTourneau, Pfizer; YJ Shukla, EOCCO/Moda Health; Thu-Mai Duong, Sanofi

(*) Provided verbal testimony
Written testimony: Posted to OSU Website
I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:32 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Approval of Agenda and April 2022 Minutes presented by Roger Citron
   \textbf{ACTION: Motion to approve, 2\textsuperscript{nd}, Dr. Helm abstained and everyone else in favor}
D. Department Update provided by Andrew Gibler, PharmD

II. CONSENT AGENDA TOPICS

A. Tetracycline Quantity Limit
   \textbf{Recommendation:}
   - Incorporate the proposed quantity limits in the Tetracycline prior authorization criteria
B. Oncology Prior Authorization (PA) Updates
   \textbf{Recommendations:}
   - Add: Carvykti\textsuperscript{™} (ciltaclabtagene autoleucel); Pluvicto\textsuperscript{™} (lutetium Lu 177 vipivotide tetraxetan); Opdualag\textsuperscript{™} (nivolumab; relatlimab-rmbw); and Vonjo\textsuperscript{™} (pacritinib) to Table 1 in the Oncology Agents PA criteria
C. Orphan Drug Policy Updates
   \textbf{Recommendation:}
   - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Vijoice\textsuperscript{™} (alpelisib) and Pyrukynd\textsuperscript{™} (mitapivat) based on FDA-approved labeling
   \textbf{ACTION: Motion to Approve, 2\textsuperscript{nd}, all in favor}

III. DUR ACTIVITIES

A. \textbf{ProDUR Report:} Lan Starkweather, PharmD
B. \textbf{RetroDUR Report:} Dave Engen, PharmD
C. \textbf{Oregon State Drug Review:} Kathy Sentena, PharmD
   - Pre- and Post-Exposure Prophylaxis of HIV
   - Anti-SARS-CoV-2 Therapeutics can Effectively Treat, Prevent COVID-19 Infection

IV. DUR NEW BUSINESS

A. \textbf{Sublingual Buprenorphine Policy Evaluation:} Sarah Servid, PharmD
   \textbf{Recommendation:} No policy changes recommended
   \textbf{ACTION: Motion to approve, 2\textsuperscript{nd}, all in favor}
B. **ADHD Drug Utilization Evaluation and DERP Summary:**
Dave Engen, PharmD; Gary Karagodsky, PharmD; Megan Herink, PharmD

**Recommendations:**
- No PDL changes recommended based on the clinical evidence
- Continue to monitor for the use of combination therapies and evaluate for any changes in trends over time
- Consider education about the need for appropriate treatment of mental health disorders in those with ADHD
- Evaluate costs in executive session

**Public Comment:** Patrick Harvey, Supernus Pharmaceuticals

**ACTION:** The Committee recommended adding Qelbree adult max dose to the tale and to look at max doses for ER versions in the table and bring back to the October meeting

**Motion to approve, 2nd, five in favor and one opposed**

V. **PREFERRED DRUG LIST NEW BUSINESS**

A. **Diuretic Literature Scan with New Drug Evaluation (NDE):** Megan Herink, PharmD

**Recommendations:**
- No PDL changes recommended based on the clinical evidence
- Maintain finerenone as non-preferred on the PDL
- Implement PA to limit use to patients with CKD and T2DM on background therapy with an ACE-I or ARB
- Evaluate costs in executive session

**Public Comment:** Patrick Harvey, Supernus Pharmaceuticals

**ACTION:** The Committee recommended adding Qelbree adult max dose to the tale and to look at max doses for ER versions in the table and bring back to the October meeting

**Motion to approve, 2nd, five in favor and one opposed**

B. **Targeted Immune Modulators for Asthma and Drugs for Inflammatory Skin Conditions**
Deanna Moretz, PharmD

**Recommendations:**
- Update PA criteria for drugs used to manage Atopic Dermatitis (AD) to reflect update to Guideline Note 21 to include facial involvement in the severity assessment of inflammatory skin conditions and add severe vitiligo as a funded condition
- Rename AD and psoriasis PA criteria to “Topical Agents for Inflammatory Skin Conditions”
- Add topical ruxolitinib and maintain as non-preferred
- Rename “Monoclonal Antibodies for Severe Asthma” PA criteria “TIMs for Severe Asthma and Atopic Dermatitis”
- Add oral abrocitinib, injectable tralokinumab and tezepelumab injection and maintain as non-preferred
- Include severe AD as an FDA-approved diagnosis for upadacitinib in the “TIMs for Autoimmune Conditions” PA
- Revise PA criteria to reduce the threshold for blood eosinophils to 150 cells/μL for monoclonal antibodies prescribed for eosinophilic asthma, update definition of severe asthma exacerbation, and include use of OCS in asthma exacerbation criteria
- Evaluate costs in executive session

**Public Comment:** Valeri Ng, LEO Pharma; Charles Lovan, AbbVie; Victoria Romo-LeTourneau, Pfizer; Rochelle Yang, Teva Pharmaceuticals; Thu-Mai Duong, Sanofi

**ACTION:** Motion to approve, 2nd, all in favor

**C. Mycobacterium Agents Class Review:** Sara Fletcher, PharmD

**Recommendations:**
- Add the Mycobacterium Agents class to the PDL
- Make bedaquiline preferred given strong recommendations for use in drug-resistant TB
- Make rifampin and isoniazid preferred first-line treatment regimens for both drug-susceptible TB and latent TB
- Make pyrazinamide and ethambutol preferred components of first-line treatment regimens for drug-susceptible TB
- Make rifapentine preferred as a component of a first-line treatment regimen for latent TB and an alternative regimen for drug susceptible pulmonary TB
- Evaluate costs in executive session

**Public Comment:** Heidi Behm, OHA Public Health TB Program

**ACTION:** The Committee instead recommended removing the PA requirement and PDL status for bedaquiline and keep all agents open access

**Motion to approve, 2nd, all in favor**

**E. Estrogen Class Update:** Deferred

---

**VI. EXECUTIVE SESSION**

**Members Present:** Stacy Ramirez, PharmD; Caryn Mickelson, PharmD; Robin Moody, MPH; Russ Huffman, PMHNP; Mark Helm, MD; Cat Livingston, MD

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Sara Fletcher, PharmD; Kathy Sentena, PharmD; Lan
VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. ADHD Drug Utilization Evaluation and DERP Summary
   Recommendation: Make methylphenidate tab ER 24 (Concerta and its generic) preferred
   ACTION: Motion to approve, 2nd, all in favor

B. Diuretic Literature Scan with NDE:
   Recommendation: No changes to the PDL were recommended
   ACTION: Motion to approve, 2nd, all in favor

C. Targeted Immune Modulators for Asthma and Drugs for Inflammatory Skin Conditions
   Recommendation: Make topical steroid products betamethasone-propylene glycol cream,
   clobetasol propionate solution, desoximetasone cream, and hydrocortisone cream products
   that have utilization preferred changes
   ACTION: Motion to approve, 2nd, all in favor

D. Mycobacterium Agents Class Review
   Recommendation: Remove PDL coding for bedaquiline and keep all agents open access
   ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN